[HTML][HTML] PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
…, M Puccetti, M Bocchini, S Ravaioli, M Celli… - Scientific reports, 2018 - nature.com
Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level
at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are …
at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are …
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-choline PET/CT scan before salvage radiation …
…, R Mazzarotto, C Pettinato, M Celli… - Journal of Nuclear …, 2014 - Soc Nuclear Med
The aim of the study was to assess which factors may influence 11 C-choline PET/CT
detection rate in a population of recurrent prostate cancer (PCa) patients listed for salvage …
detection rate in a population of recurrent prostate cancer (PCa) patients listed for salvage …
68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients
…, F Matteucci, U De Giorgi, L Uccelli, M Celli… - European journal of …, 2018 - Springer
Purpose We studied the usefulness of 68 Ga-prostate-specific membrane antigen (PSMA)
PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence (…
PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence (…
The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients
C Nanni, E Zamagni, M Celli, P Caroli… - Clinical nuclear …, 2013 - journals.lww.com
Aim The objective of this study was to analyze the prognostic value of 18 F-FDG PET/CT after
therapy in patients with multiple myeloma (MM). Patients and Methods One hundred seven …
therapy in patients with multiple myeloma (MM). Patients and Methods One hundred seven …
Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma
…, C Gorospe, JK Chung, I Kuzu, M Celli… - Journal of Nuclear …, 2014 - Soc Nuclear Med
The International Atomic Energy Agency sponsored a large, multinational, prospective study
to further define PET for risk stratification of diffuse large B-cell lymphoma and to test the …
to further define PET for risk stratification of diffuse large B-cell lymphoma and to test the …
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study
…, P Castellucci, D Rubello, G Martorana, M Celli… - European journal of …, 2011 - Springer
Purpose The influence of androgen deprivation therapy (ADT) on 11 C-choline uptake in
patients with prostate cancer (PC) has not yet been clarified. The aim of our study was to …
patients with prostate cancer (PC) has not yet been clarified. The aim of our study was to …
Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma
…, JC Meneghetti, F Redondo, M Celli… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Bone marrow is an important extranodal site in diffuse large B-cell lymphoma (DLBCL), and
marrow histology has been incorporated into the new National Comprehensive Cancer …
marrow histology has been incorporated into the new National Comprehensive Cancer …
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer …
…, M Sansovini, ML Belli, M Monti, F Foca, M Celli… - European Journal of …, 2020 - Springer
Purpose Radioligand therapy (RLT) with 177 Lu-PSMA-617 is a promising option for patients
with metastatic castration-resistant prostate cancer (mCRPC). The present study was …
with metastatic castration-resistant prostate cancer (mCRPC). The present study was …
[HTML][HTML] Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After …
M Celli, P Caroli, E Amadori, D Arpa, L Gurrieri… - Frontiers in …, 2021 - frontiersin.org
Background MRI-based differential diagnosis of glioma recurrence (GR) and treatment-induced
changes (TICs) remain elusive in up to 30% of treated glioma patients. We aimed to …
changes (TICs) remain elusive in up to 30% of treated glioma patients. We aimed to …
[HTML][HTML] Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST …
A Sarnelli, ML Belli, V Di Iorio, E Mezzenga, M Celli… - Molecules, 2019 - mdpi.com
Radio-ligand therapy (RLT) with 177 Lu-PSMA-617 is a promising option for patients with
metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study (…
metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study (…